Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M799Revenue $M313Net Margin (%)3.8Z-Score2.7
Enterprise Value $M882EPS $0.9Operating Margin %6.8F-Score3
P/E(ttm))61.1Cash Flow Per Share $0.9Pre-tax Margin (%)6.0Higher ROA y-yN
Price/Book1.610-y EBITDA Growth Rate %3.5Quick Ratio3.7Cash flow > EarningsY
Price/Sales2.35-y EBITDA Growth Rate %-4.3Current Ratio4.5Lower Leverage y-yN
Price/Cash Flow17.0y-y EBITDA Growth Rate %0.7ROA % (ttm)2.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)2.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M37.5ROI % (ttm)5.1Gross Margin Increase y-yN

Gurus Latest Trades with EBS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
EBSJohn Burbank 2014-06-30 Sold Out -0.01%$20.42 - $26.78
($23.3)
$ 21.31-8%Sold Out0
EBSJoel Greenblatt 2014-03-31 Buy 0.1%$22.85 - $28.09
($25.19)
$ 21.31-15%New holding, 258760 sh.258,760
EBSJohn Burbank 2014-03-31 Buy 0.01%$22.85 - $28.09
($25.19)
$ 21.31-15%New holding, 7987 sh.7,987
EBSJohn Rogers 2014-03-31 Sold Out -0.04%$22.85 - $28.09
($25.19)
$ 21.31-15%Sold Out0
EBSJohn Rogers 2013-12-31 Add0.02%$17.71 - $23.95
($20.84)
$ 21.312%Add 105.79%122,650
EBSJohn Rogers 2013-09-30 Add0.01%$15.22 - $19.43
($17.88)
$ 21.3119%Add 116.73%59,600
EBSJohn Rogers 2013-06-30 Buy 0.01%$13.08 - $15.73
($14.48)
$ 21.3147%New holding, 27500 sh.27,500
EBSJoel Greenblatt 2013-03-31 Sold Out -0.14%$13.95 - $16.9
($15.67)
$ 21.3136%Sold Out0
EBSJoel Greenblatt 2012-12-31 Buy 0.14%$12.91 - $16.09
($14.64)
$ 21.3146%New holding, 147099 sh.147,099
EBSKen Fisher 2012-12-31 Add$12.91 - $16.09
($14.64)
$ 21.3146%Add 21.09%401,700
EBSJoel Greenblatt 2011-12-31 Sold Out -0.08%$15.43 - $19.64
($17.41)
$ 21.3122%Sold Out0
EBSKen Fisher 2011-06-30 Add0.01%$20.66 - $24.98
($23.2)
$ 21.31-8%Add 160.57%300,305
EBSJoel Greenblatt 2011-06-30 Reduce-0.05%$20.66 - $24.98
($23.2)
$ 21.31-8%Reduce -20.74%26,620
EBSJoel Greenblatt 2011-03-31 Add0.17%$20.64 - $24.55
($22.62)
$ 21.31-6%Add 243.58%33,585
EBSKen Fisher 2011-03-31 Buy 0.01%$20.64 - $24.55
($22.62)
$ 21.31-6%New holding, 115250 sh.115,250
EBSJoel Greenblatt 2010-12-31 Buy 0.07%$17.59 - $23.8
($19.23)
$ 21.3111%New holding, 9775 sh.9,775
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EBS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
EBS Ken Fisher 2014-06-30468,7571.250.02+17.58%
EBS Joel Greenblatt 2014-06-30221,9280.590.06-14.23%
EBS John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


EBS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kramer RobertCFO 2014-04-16Sell50,189$24.34-10.48view
Havey AdamEVP, Biodefense Divison 2014-03-12Sell11,562$27.5-20.76view
Havey AdamEVP, Biodefense Divison 2014-03-11Sell17,655$26.96-19.18view
Abdun-Nabi DanielCEO 2013-11-30Buy749$19.0814.2view
Abdun-Nabi DanielCEO 2013-05-31Buy800$12.0780.53view
El-Hibri FuadChairman, 10% Owner 2013-04-18Sell114,872$15.0344.98view
El-Hibri FuadChairman, 10% Owner 2012-12-04Sell43,064$15.0844.5view
El-Hibri FuadChairman, 10% Owner 2012-12-03Sell56,936$15.1443.92view
Kramer RobertEVP Corporate Svs. Div 2012-09-06Sell28,000$14.8247.03view
Harsanyi ZsoltDirector 2011-06-07Sell21,600$23.97-9.09view

Press Releases about EBS :

    Quarterly/Annual Reports about EBS:

    News about EBS:

    Articles On GuruFocus.com
    Emergent BioSolutions Inc. Reports Operating Results (10-Q) Nov 05 2010 
    Emergent BioSolutions Inc. Reports Operating Results (10-Q) Aug 06 2010 
    Emergent BioSolutions Inc. (EBS) President & COO Daniel Abdun-nabi sells 18,150 Shares Jul 30 2010 
    Weekly CEO Sells Highlight: Yum! Brands Inc, Marchex Inc, iGate Corp, and Emergent BioSolutions Inc. Jul 25 2010 
    Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 18,800 Shares Jul 23 2010 
    Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 130,100 Shares Jul 22 2010 
    Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 84,433 Shares Jul 19 2010 
    Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 52,000 Shares May 14 2010 
    Emergent BioSolutions Inc. Reports Operating Results (10-Q) May 06 2010 
    Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 25,000 Shares Apr 29 2010 


    More From Other Websites
    Emergent BioSolutions to Webcast Presentation at Credit Suisse 2014 Healthcare Conference Oct 20 2014
    Emergent BioSolutions to Webcast Presentation at Credit Suisse 2014 Healthcare Conference Oct 20 2014
    Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% Oct 20 2014
    GW Pharmaceuticals Down on Disappointing Mid-Stage Data Oct 15 2014
    15.10.2014 - Savings Study 2014: Is There Still Something to Feed the Piggy Bank? Oct 15 2014
    Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% Oct 14 2014
    Prosensa Holding N.V. (RNA) in Focus: Stock up 8.5% Oct 14 2014
    Emergent BioSolutions to Release Third Quarter 2014 Financial Results and Conduct a Conference Call... Oct 09 2014
    Emergent BioSolutions Revamps Business to Drive Earnings Oct 08 2014
    EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Regulation FD Disclosure Oct 07 2014
    Emergent BioSolutions Initiates Pivotal Study on BioThrax Sep 24 2014
    Emergent BioSolutions Initiates Final Pivotal Study to Support Licensure of BioThrax at Large Scale Sep 23 2014
    Emergent BioSolutions Wins $29M Anthrax Vaccine Deal Sep 10 2014
    Emergent BioSolutions Awarded Contract to Develop a Dry Formulation of NuThrax, a Next Generation... Sep 08 2014
    Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate Aug 20 2014
    Morphosys AG On License Agreement With Emergent To Co-Develop And Commercialize Prostate Cancer Drug... Aug 20 2014
    EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 20 2014
    MorphoSys and Emergent BioSolutions Sign License Agreement to Co-Develop and Commercialize Prostate... Aug 19 2014
    Emergent BioSolutions and MorphoSys Sign License Agreement to Co-Develop and Commercialize Prostate... Aug 19 2014
    MorphoSys and Emergent BioSolutions Sign License Agreement to Co-Develop and Commercialize Prostate... Aug 19 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK